USPTO serial 79264394
QIAGEN - SAMPLE TO OUTCOME
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 21, 2020
- Examiner
- MAJCHER HARTNETT, MEGAN K
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with QIAGEN - SAMPLE TO OUTCOME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,700
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Keith A. Weltsch
Keith A. Weltsch Scully, Scott, Murphy & Presser, P.C.400 Garden City Plaza, Suite 300Garden City, NY 11530UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable and recorded computer software for data and document management, medical teaching; downloadable and recorded computer software and related downloadable databases for use in preparing and managing nucleic acid and protein assay analysis and for managing quality control, validation, interpretation, reporting, clinical decision support, data management, integration with medical records, physician portals, laboratory networking, professional healthcare and trial matching services all related to molecular and genomic analysis; downloadable and recorded computer software, namely, evidence-based decision support software used as an aid in the interpretation of variants observed in genomic sequencing data; downloadable and recorded computer software for evaluation of genomic variants in the context of software for searching and allocating published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels, and/or clinical-trials; downloadable and recorded computer software for preparing, interpretation and managing of bioinformatics analyses, optionally combined with data management, graphical viewing and output options; downloadable and recorded computer programs and software for biological data mining; downloadable and recorded computer programs and software for developing bioinformatics database for others; bio-chips for research or scientific purposes; DNA-chips; RNA-chips; next-generation sequencing (NGS) data processor; bioinformatics data processor; computer hardware and downloadable and recorded computer software for collecting, storing, analyzing, visualizing, and interpreting bioinformatics, genomics, and phenomics data sets; computer hardware and downloadable and recorded computer software for the monitoring of pathogens; downloadable computer databases for bioinformatics, genomics, phenomics, microbiome, metagenomics, organism-and -pathogen-specific genotype records, and organism and pathogen-specific phenotype information; downloadable and recorded computer software for use in the integration, analysis and visualization of biomedically relevant information allowing users to explore compound, target, assay, biological pathway and disease information; downloadable and recorded computer software and databases for the analysis of genomes, exomes, targeted amplicons, transcriptomes, and epigenetic NGS sequencing data; downloadable and recorded computer software, software development tools, and visualization software modules, for analysis, discovery, verification, and validation of disease biomarkers | ACTIVE | — |
| 010 | Medical diagnostic testing instruments for processing and analysis of genetic samples primarily for single-cell genomic, transcriptomic, or proteomic analysis; medical and diagnostic apparatus for testing DNA and RNA samples, using gene expression tests, gene expression profiling assays, genetic information and data, protein biomarkers, clinical data, and/or demographic information; testing apparatus for medical purposes for testing DNA and RNA samples sold as a unit with downloadable bioinformatics and machine learning algorithm software and medical data software to support treatment decisions; medical testing apparatus for testing DNA and RNA samples and quantifying biomarker levels and relative expression of host response genes; medical apparatus and instruments for detecting tumor cancer, heredity and genetic diseases; medical testing apparatus for samples of body fluids, tissue and organs; genome machine for medical purposes, namely, apparatus for DNA and RNA medical testing; diagnostic apparatus for the detection of cancer, genetic or heredity diseases | ACTIVE | — |
| 042 | Providing temporary use of online non-downloadable software for use in collecting, organizing and managing data on bioinformatics, genomics, phenomics, microbiome, and metagenomics applications; hosting of computer databases featuring information relating to bioinformatics, genomics, phenomics, microbiome, metagenomics, organism- and pathogenspecific genotype records, and organism and pathogen-specific phenotype information; consulting relating to computer programming for acquiring, creating, sharing, managing, mining, analyzing, visualizing, interpreting and applying genomics and phenomics records; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from patients; providing an online, non-downloadable computer software platform for purposes of storing and providing information about an individual's disease profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice; providing temporary use of on-line nondownloadable software and applications for genome analysis, developing personal treatment strategies for patients with diagnosed cancer and other diseases or disorders; conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; providing information about medical and scientific research in the field of bioinformatics to enable physicians and healthcare professionals to optimize treatment in clinical practice; computer programming services for medical reporting, namely, for creating, sharing, managing, mining, analyzing, visualizing, interpreting and applying genomics and phenomics records; scientific research services, namely, providing information relating to research in the field of specific molecular and genomic sciences for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific advice in the fields of cancer biology, cancer treatment, pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from patients with cancer and other diseases and disorders | ACTIVE | — |
| 044 | Providing medical information and medical advice in the fields of retrieval, integration, correlation, analysis and interpretation of genomic data, sequencing data and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data and patient-specific data, molecular test results, clinical trial data; medical consulting services in the fields of health, medical care, biotechnology, bioinformatics, life sciences, pharmaceuticals and medicine; providing medical information in the fields of health, healthcare, life sciences, biotechnology, pharmaceuticals and pharmaceutical safety, bioinformatics, and genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing medical information on drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocols; medical consulting services in the field of genomics and biological sequence processing and analysis for medical diagnosis and treatment purposes; providing medical information for the purposes of medical diagnosis and treatment in the field of molecular genetics; identification and testing of DNA samples for health care purposes; health care services, namely, medical genomics and data science consultancy to provide optimal health and disease prevention or treatment to patients; providing health information relating to genetics and diagnostics via the Internet; bioinformatics analysis for medical diagnostic and personalized treatment purposes; nucleic acid analysis and screening for medical diagnostic and treatment purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Qiagen GmbH
- Other trademarks owned by Qiagen GmbH
- Other trademarks owned by Qiagen GmbH
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named QIAGEN - SAMPLE TO OUTCOME
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 21, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Dec 5, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 12, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 12, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 21, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 21, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 5, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 5, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 15, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 2, 2020 | ALIE | ASSIGNED TO LIE | — |
| Mar 25, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 25, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 25, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 25, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 25, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 5, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 4, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 4, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 28, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 6, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 6, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 14, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 13, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 9, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 9, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 1, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |